Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is focused on establishing a position as a first mover in the artificial intelligence (“AI”)-powered, drug-discovery market. According to the announcement, the company anticipates the space will reach $20 billion in the next three years. As part of its focus, POAI is working to leverage its existing pharma relationships to move its proprietary platform, PeDAL(TM), from the research lab into the pipelines of oncology drug-discovery companies. This strategy is possible because the company has completed the proof of concept for PeDAL. The company announced that its artificial intelligence program, CoRE(TM), combined with tumor profile data, human tumor samples and active machine learning, powers PeDAL to determine the most effective drug treatment for specific cancer types. CoRE learns with each iteration, thereby improving the accuracy of its predicted treatment outcomes. “The demonstration of our drug discovery platform provides the proof of concept that our pharmaceutical partners have been waiting for,” said Predictive Oncology Inc. CEO and chair J. Melville in the press release. “We expect to meet the existing demand from pharmaceutical companies for our solutions, which will help companies streamline their drug discovery processes, increasing the probability of technical success of new molecules entering the clinic. PeDAL provides an additional decision making tool to oncology drug development companies as they decide which tumor types to invest in and pursue.”

To view the full press release, visit https://ibn.fm/XTCCp

About Predictive Oncology Inc.

Predictive Oncology a knowledge-driven company focused on applying artificial intelligence (“AI”) to develop personalized cancer therapies, which can lead to more effective treatments and improved patient outcomes. Using artificial intelligence, Predictive Oncology uses a database of 150,000+ cancer tumors, categorized by patient type, against drug compounds to determine optimal therapies to be used to ultimately eliminate cancer. As the drug-discovery community has now realized, a genomics-based approach to cancer research and drug development is insufficient to achieve the promise of personalized therapeutics. Predictive Oncology instead takes a multiomic approach, which considers the vast multitude of factors that make each cancer unique. For more information about the company, please visit www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork.